Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $5.98 in the prior trading day, Abeona Therapeutics Inc (NASDAQ: ABEO) closed at $5.9, down -1.34%. In other words, the price has decreased by -$1.34 from its previous closing price. On the day, 0.87 million shares were traded. ABEO stock price reached its highest trading level at $6.03 during the session, while it also had its lowest trading level at $5.855.
Ratios:
Our goal is to gain a better understanding of ABEO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.58 whereas as Long-Term Debt/Eq ratio is at 0.37.
On March 05, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $16.
On July 03, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.H.C. Wainwright initiated its Buy rating on July 03, 2024, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 06 ’25 when Vazzano Joseph Walter sold 17,795 shares for $6.76 per share. The transaction valued at 120,294 led to the insider holds 491,246 shares of the business.
Seshadri Vishwas sold 50,676 shares of ABEO for $342,570 on Jun 06 ’25. The Chief Executive Officer now owns 1,303,761 shares after completing the transaction at $6.76 per share. On Jun 06 ’25, another insider, O’Malley Brendan M., who serves as the SVP, General Counsel of the company, sold 10,470 shares for $6.76 each. As a result, the insider received 70,777 and left with 378,245 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 305917376 and an Enterprise Value of 241646736.
Stock Price History:
The Beta on a monthly basis for ABEO is 1.54, which has changed by 0.3915094 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, ABEO has reached a high of $7.32, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is -0.31%, while the 200-Day Moving Average is calculated to be 2.32%.
Shares Statistics:
The stock has traded on average 1.72M shares per day over the past 3-months and 800360 shares per day over the last 10 days, according to various share statistics. A total of 48.95M shares are outstanding, with a floating share count of 45.31M. Insiders hold about 11.43% of the company’s shares, while institutions hold 59.25% stake in the company. Shares short for ABEO as of 1749772800 were 6462782 with a Short Ratio of 3.76, compared to 1747267200 on 5892747. Therefore, it implies a Short% of Shares Outstanding of 6462782 and a Short% of Float of 13.520001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Abeona Therapeutics Inc (ABEO) is currently being evaluated by a team of 4.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.28, with high estimates of $1.98 and low estimates of -$0.33.
Analysts are recommending an EPS of between $1.35 and -$1.2 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is -$0.21, with 4.0 analysts recommending between $0.04 and -$0.35.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $6.61M. There is a high estimate of $10.87M for the next quarter, whereas the lowest estimate is $2.33M.
Based on 7 analysts’ estimates, the company’s revenue will be $106.05M in the next fiscal year. The high estimate is $130.35M and the low estimate is $64.75M.
